SOLICITATION NOTICE
B -- Evaluation of insulin-like growth factor-1 plasma biomarkers and multiple myeloma among participants in two cohort studies: Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the Alpha-ŽTocopherol and the Beta-Carotene Cancer Prevention Study
- Notice Date
- 8/14/2009
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90184-AV
- Archive Date
- 9/9/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis, services regarding evaluation of insulin-like growth factor-1 plasma biomarkers and multiple myeloma among participants in two cohort studies: Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the Alpha-¬Tocopherol and the Beta-Carotene Cancer Prevention Study (ATBC) with Boston Children's Hospital; Department of Laboratory Medicine; Boston, Massachusetts; 02115. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 541690 the business size standard is 6.5 M employees. The period of performance for this procurement is 9 months from the date of award. The purpose of this procurement is to support a project investigating whether prediagnostic plasma/serum levels of selected interleukin-6 (IL-6) pathway biomarkers (1L-6, sIL6R, C- reactive protein) are associated with risk of multiple myeloma. A pooling project involving specimens from nine cohort studies is being conducted by the OEEB to evaluate the association of biomarkers of the 1L-6 pathway (1L-6, s1L6R, C-reactive protein) with incident multiple myeloma and will contribute novel information on multiple myeloma etiology. The entire pooling project will involve an estimated total sample size of 560 cases and 1120 controls; two NCI cohorts, the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the Alpha-¬Tocopherol and the Beta-Carotene Cancer Prevention Study (ATBC) will contribute 195 cases and 390 controls collectively. For this procurement, plasma specimens from PLCO and serum samples from ATBC will he sent to a laboratory to be assayed. The resulting measurements will be included as part of a multi-study pooling project (nine cohort studies in total) investigating these analytes. In addition, the study will involve the measurement of IL-G, sIL6R and C-reactive protein in plasma/serum samples from 195 multiple myeloma cases, 390 controls, and an additional 76 blinded quality controls samples. The laboratory measurements to be performed under this procurement are being performed as part of a multi-study pooling project (nine cohort studies in total) investigating the analytes. The other studies (from extramurally-funded universities and research institutes) that will be participating in the pooling project will be sending their samples to the Department of Laboratory Medicine at the Children's Hospital, a world leader in studying systemic inflammation markers and whose experienced lab has demonstrated excellent assay reproducibility. For scientific comparability, it is critical that the samples from the NCI studies be assayed at the same laboratory as the samples from the other studies participating in this pooling project. For these reasons, there is no other known source to the NCI to complete the services outlined in this procurement. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on August 25, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Ashley Virts: virtsa@mail.nih.gov. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90184-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90184-AV/listing.html)
- Record
- SN01912229-W 20090816/090815001954-0ca2292ae8437a804868f3810b26300b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |